Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 10/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.66 |
| ▸ | KDR | P35968 | 8/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.63 |
| ▸ | RET | P07949 | 4/20 | 0.63 |
| ▸ | SRC | P12931 | 3/20 | 0.63 |
| ▸ | ABL1 | P00519 | 3/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.63 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.63 |
| ▸ | PLK4 | O00444 | 2/20 | 0.63 |
| ▸ | AURKA | O14965 | 2/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.63 |
| ▸ | FYN | P06241 | 2/20 | 0.63 |
| ▸ | LYN | P07948 | 2/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.63 |
| ▸ | AXL | P30530 | 2/20 | 0.63 |
| ▸ | FRK | P42685 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12835115 | 0.91 | RIPK2 (0.55) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL10201086 | 0.88 | RAF1 (0.73) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL13282687 | 0.88 | RAF1 (0.66) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL257980 | 0.85 | RAF1 (0.82) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL10203624 | 0.84 | RAF1 (0.79) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL10163311 | 0.83 | RAF1 (0.76) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL19888730 | 0.82 | RAF1 (0.78) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL13529089 | 0.82 | RAF1 (0.72) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL1532339 | 0.82 | RAF1 (0.77) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL12391532 | 0.81 | RAF1 (0.76) | RAF1EPHX2KDRMAPK14RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897623-B2 | FDA Orange book listed patent for sorafenib tosylate; tablets | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885EPHX2 445/4885KDR 567/4885 |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | MAPK1, MAPK8, MAPK3 | RAF1 452/4885EPHX2 419/4885KDR 2141/4885 |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | BRAF, RAF1, ARAF | RAF1 2/4885EPHX2 483/4885KDR 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.